Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bcl-2
inhibits apoptosis induced by a wide variety of stimuli. In contrast, the
Bcl-2
homologue, Bax, antagonizes
Bcl-2
's death protecting function.
Bcl-2
forms protein-protein homodimers with itself and heterodimers with Bax, and previous experiments have shown that point mutations in
Bcl-2
can abrogate Bax binding while leaving homodimerization intact. These mutagenesis results can be interpreted to suggest that
Bcl-2
has separate binding sites that are responsible for homodimer and heterodimer formation. Results from yeast two-hybrid studies have also suggested that homodimerization and heterodimerization reflect distinct modes of interaction. However, using quantitative plate binding assays, we now show that Bax as well as peptides derived from the
BH3
domains of Bax and Bak block both
Bcl-2
/Bax binding and
Bcl-2
/
Bcl-2
binding. Similar assays demonstrate that Bcl-xL can form both homodimers and heterodimers and that these interactions are also inhibited by Bax and the
BH3
-derived peptides. These results demonstrate that the same binding motifs are responsible for both homodimerization and heterodimerization of
Bcl-2
family members.
...
PMID:A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members. 911 Oct 42
Apoptosis as a form of programmed cell death (PCD) in multicellular organisms is a well-established genetically controlled process that leads to elimination of unnecessary or damaged cells. Recently, PCD has also been described for unicellular organisms as a process for the socially advantageous regulation of cell survival. The human
Bcl-2
family member Bak induces apoptosis in mammalian cells which is counteracted by the Bcl-x(L) protein. We show that Bak also kills the unicellular fission yeast Schizosaccharomyces pombe and that this is inhibited by coexpression of human Bcl-x(L). Moreover, the same critical
BH3
domain of Bak that is required for induction of apoptosis in mammalian cells is also required for inducing death in yeast. This suggests that Bak kills mammalian and yeast cells by similar mechanisms. The phenotype of the Bak-induced death in yeast involves condensation and fragmentation of the chromatin as well as dissolution of the nuclear envelope, all of which are features of mammalian apoptosis. These data suggest that the evolutionarily conserved metazoan PCD pathway is also present in unicellular yeast.
...
PMID:Human Bak induces cell death in Schizosaccharomyces pombe with morphological changes similar to those with apoptosis in mammalian cells. 911 15
Programmed cell death is essential in organ development and tissue homeostasis and its deregulation is associated with the development of several diseases in mice and humans. The precise mechanisms that control cell death have not been elucidated fully, but it is well established that this form of cellular demise is regulated by a genetic program which is activated in the dying cell. Here we report the identification, cloning and characterization of harakiri, a novel gene that regulates apoptosis. The product of harakiri, Hrk, physically interacts with the death-repressor proteins
Bcl-2
and Bcl-X(L), but not with death-promoting homologs, Bax or Bak. Hrk lacks conserved BH1 and BH2 regions and significant homology to
Bcl-2
family members or any other protein, except for a stretch of eight amino acids that exhibits high homology with
BH3
regions. Expression of Hrk induces cell death which is inhibited by
Bcl-2
and Bcl-X(L). Deletion of 16 amino acids including the conserved
BH3
region abolished the ability of Hrk to interact with
Bcl-2
and Bcl-X(L) in mammalian cells. Moreover, the killing activity of this mutant form of Hrk (Hrk deltaBH3) was eliminated or dramatically reduced, suggesting that Hrk activates cell death at least in part by interacting with and inhibiting the protection afforded by
Bcl-2
and Bcl-X(L). Because Hrk lacks conserved BH1 and BH2 domains that define
Bcl-2
family members, we propose that Hrk and Bik/Nbk, another
BH3
-containing protein that activates apoptosis, represent a novel class of proteins that regulate apoptosis by interacting selectively with survival-promoting
Bcl-2
and Bcl-X(L).
...
PMID:harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). 913 Jul 13
Interactions among proteins in the
Bcl-2
family regulate the onset of programmed cell death. Previous work has shown that the death-inhibiting family members
Bcl-2
and Bcl-xL form heterodimers with the death-promoting homologue Bax and that certain site-directed mutants of
Bcl-2
and Bcl-xL lose both biological activity and the ability to bind Bax. To better understand the structural basis of heterodimer formation, we have used a yeast two-hybrid assay to screen for mutants of Bax that regain the ability to bind to these inactive
Bcl-2
(G145A) and Bcl-xL(G138A) mutants. This screen identified a series of C-terminally truncated Bax molecules that contain complete
BH3
(
Bcl-2
homology domain 3) domains but that have lost BH1 and BH2 sequences. These results indicate that while the
Bcl-2
and Bcl-xL mutants fail to bind full-length Bax, they still retain a binding site for the critical
BH3
domain. This suggests that conformational constraints in full-length Bax regulate its ability to bind to other
Bcl-2
family members. Furthermore, we demonstrate that the normally inert
Bcl-2
(G145A) mutant effectively blocks apoptosis induced by a C-terminally truncated Bax molecule, but does not block apoptosis induced by wild-type Bax. This demonstrates that cell protection can be effected by directly binding pro-apoptotic members of the
Bcl-2
family.
...
PMID:Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation. 920 7
Bik is a potent pro-apoptotic protein, which complexes with various anti-apoptotic proteins such as
Bcl-2
, Bcl-xL, 19-kDa adenovirus E1B, and EBV-BHRF1. The mechanism by which Bik promotes cell death is not known. It shares a conserved domain,
BH3
, with other pro-apoptotic proteins, Bax, Bak, Bid, and Hrk, and certain anti-apoptosis proteins such as
Bcl-2
and Bcl-xL. Mutations within the
BH3
domain of Bik abrogate its ability to induce cell death and to complex with anti-apoptosis proteins. This result is consistent with the hypothesis that Bik may promote cell death by complexing with and antagonizing the activity of endogenous cellular anti-apoptosis proteins such as
Bcl-2
and Bcl-xL. To elucidate the relationship between protein complex formation and induction of cell death, we have identified the minimal sequences of Bik, from a library of N-terminal and C-terminal deletion mutants, required for interaction with
Bcl-2
and Bcl-xL and for inducing efficient cell death. Two-hybrid analysis in yeast and immunoprecipitation analysis of proteins expressed in mammalian cells indicate that a 52-amino acid region (amino acids 43-94) of Bik, encompassing the
BH3
domain, is sufficient for efficient heterodimerization with
Bcl-2
and Bcl-xL. Protein interaction studies further reveal that an 18-amino acid region, encompassing the
BH3
domain (residues 57-74), constitutes the core heterodimerization domain. Functional analysis indicates that a Bik deletion mutant expressing residues 43-120, which efficiently heterodimerizes with the anti-apoptosis proteins
Bcl-2
and Bcl-xL, is defective in eliciting cell death. In contrast, a mutant expressing additional C-terminal sequences (amino acids 43-134) interacts with the survival proteins and elicits efficient cell death. Our results suggest that for Bik-mediated cell death, the heterodimerization activity encoded by the
BH3
domain alone is insufficient and raise the possibility that Bik may induce cell death autonomous of heterodimerization with survival proteins such as
Bcl-2
and Bcl-xL.
...
PMID:Functional dissection of the pro-apoptotic protein Bik. Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death. 930 12
Bak has been shown to both promote apoptosis and to inhibit cell death while two other members of the
Bcl-2
family of proteins, Bcl-XL and
Bcl-2
delay apoptosis induced by various stimuli including chemotherapeutic agents. We generated clones with stable expression of Bak wild-type (wt) and Bak with its
BH3
(delta78-86) domain deleted (deltaBH3) in FL5.12 cells or FL5.12 cells expressing either Bcl-XL or
Bcl-2
to determine if Bak could accelerate apoptosis and antagonize the death repressor activity of Bcl-XL and
Bcl-2
during chemotherapy-induced apoptosis. We found that Bak accelerated cell death in FL5.12 cells treated with etoposide, fluorouracil or taxol. In FL5.12 cells expressing Bcl-XL and Bak wt or Bak deltaBH3, both Bak wt or Bak deltaBH3 were able to antagonize the protective effect of Bcl-XL when treated with etoposide or fluorouracil. Bak wt or Bak deltaBH3 were also able to abrogate the protective effect of
Bcl-2
in cells expressing
Bcl-2
and Bak wt or Bak deltaBH3 when challenged by etoposide or fluorouracil. Immunoprecipitation studies revealed that deletion of
BH3
disrupted heterodimerization between Bak and Bcl-XL and that both Bak wt and Bak deltaBH3 failed to interact with
Bcl-2
. These results demonstrate that Bak does not require its
BH3
domain to promote apoptosis in stably transfected cells. Furthermore, Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and
Bcl-2
.
...
PMID:Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and Bcl-2. 936 54
bax is an apoptosis-inducing member of the bcl-2 multigene family. We have studied interactions of human Bax with itself, and with the apoptosis-preventing members
Bcl-2
and Bcl-xL using a yeast two-hybrid system. Exhaustive Bax truncations were constructed and their interactions with full-length family members studied. Bax interacted similarly with itself as with the apoptosis-suppressing family members
Bcl-2
and Bcl-xL in quantitative two-hybrid studies. A region of 41 amino acids covering the recently discovered
BH3
domain of Bax was found to be necessary and sufficient for all interactions of Bax. Bax truncations containing
BH3
, but lacking BH1 and BH2 homology domains, interacted with the other family members markedly more strongly than full-length Bax, which may reflect conformational changes required for the interactions of full-length Bax. The minimum requirements for Bax homodimerization were found to be the
BH3
domain from one Bax molecule and a region covering
BH3
plus BH1 from another. We also studied the apoptosis-inducing activity of the Bax truncations upon microinjection of expression plasmids into rat fibroblasts. The
BH3
region was required for the apoptosis-inducing activity of Bax, whereas BH1, BH2 and the N-terminus of Bax were dispensable.
...
PMID:The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis. 936 57
The Bcl-2 related protein Bad is a promoter of apoptosis and has been shown to dimerize with the anti-apoptotic proteins
Bcl-2
and Bcl-XL. Overexpression of Bad in murine FL5.12 cells demonstrated that the protein not only could abrogate the protective capacity of coexpressed Bcl-XL but could accelerate the apoptotic response to a death signal when it was expressed in the absence of exogenous Bcl-XL. Using deletion analysis, we have identified the minimal domain in the murine Bad protein that can dimerize with Bcl-xL. A 26-amino-acid peptide within this domain, which showed significant homology to the alpha-helical
BH3
domains of related apoptotic proteins like Bak and Bax, was found to be necessary and sufficient to bind Bcl-xL. To determine the role of dimerization in regulating the death-promoting activity of Bad and the death-inhibiting activity of Bcl-xL, mutations within the hydrophobic
BH3
-binding pocket in Bcl-xL that eliminated the ability of Bcl-xL to form a heterodimer with Bad were tested for the ability to promote cell survival in the presence of Bad. Several of these mutants retained the ability to impart protection against cell death regardless of the level of coexpressed Bad protein. These results suggest that
BH3
-containing proteins like Bad promote cell death by binding to antiapoptotic members of the
Bcl-2
family and thus inhibiting their survival promoting functions.
...
PMID:Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. 937 35
Caspases are a family of cysteine proteases implicated in the biochemical and morphological changes that occur during apoptosis (programmed cell death). The loop domain of
Bcl-2
is cleaved at Asp34 by caspase-3 (CPP32) in vitro, in cells overexpressing caspase-3, and after induction of apoptosis by Fas ligation and interleukin-3 withdrawal. The carboxyl-terminal
Bcl-2
cleavage product triggered cell death and accelerated Sindbis virus-induced apoptosis, which was dependent on the
BH3
homology and transmembrane domains of
Bcl-2
. Inhibitor studies indicated that cleavage of
Bcl-2
may further activate downstream caspases and contribute to amplification of the caspase cascade. Cleavage-resistant mutants of
Bcl-2
had increased protection from interleukin-3 withdrawal and Sindbis virus-induced apoptosis. Thus, cleavage of
Bcl-2
by caspases may ensure the inevitability of cell death.
...
PMID:Conversion of Bcl-2 to a Bax-like death effector by caspases. 939 3
The pro-apoptotic protein Bax can homodimerize with itself and heterodimerize with the anti-apoptotic protein
Bcl-2
, but the significance of these protein-protein interactions remains unclear. Alanine substitution mutations were created in a well conserved IGDE motif found within the
BH3
domain of Bax (residues 66-69) and the resulting mutant Bax proteins were tested for ability to homodimerize with themselves and to heterodimerize with
Bcl-2
. Correlations were made with cell death induction by these mutants of Bax both in mammalian cells where Bax may function through several mechanisms, and in yeast where Bax may exert its lethal actions through a more limited repertoire of mechanisms perhaps related to its ability to form ion channels in intracellular membranes. Two of the mutants, Bax(D68A) and Bax(E69A), retained the ability to homodimerize but failed to interact with
Bcl-2
as determined by yeast two-hybrid assays and co-immunoprecipitation analysis using transfected mammalian cells. The Bax(E69A) protein exhibited a lethal phenotype in yeast, which could be specifically suppressed by co-expression of
Bcl-2
, despite its failure to dimerize with
Bcl-2
. Both the Bax(D68A) and Bax(E69A) proteins induced apoptosis when overexpressed in human 293 cells, despite an inability to bind to
Bcl-2
. Moreover, co-expression of
Bcl-2
with Bax(D68A) and Bax(E69A) rescued mammalian cells from apoptosis. In contrast, a mutant of Bax lacking the IGDE motif, Bax(DeltaIGDE), was incapable of either homodimerizing with itself or heterodimerizing with
Bcl-2
and was inactive at promoting cell death in either yeast or mammalian cells. Although failing to interact with
Bcl-2
, the Bax(D68A) and Bax(E69A) mutants retained the ability to bind to Bid, a putative Bax-activating member of the
Bcl-2
family, and collaborated with Bid in inducing apoptosis. When taken together with previous observations, these findings indicate that (i) Bax can induce apoptosis in mammalian cells irrespective of heterodimerization with
Bcl-2
and (ii)
Bcl-2
can rescue both mammalian cells and yeast from the lethal effects of Bax without heterodimerizing with it. However, these results do not exclude the possibility that
BH3
-dependent homodimerization of Bax or interactions with Bax activators such as Bid may either assist or be required for the cell death-inducing mechanism of this protein.
...
PMID:Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. 939 83
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>